Obsidian Therapeutics Secures $160.5M in Series C Funding
April 8, 2024, 9:32 pm
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Founded date: 2015
Total raised: $325.04M
Obsidian Therapeutics, a cutting-edge biotech company based in Cambridge, MA, has successfully raised a whopping $160.5 million in Series C funding. The round was spearheaded by Wellington Management, with a slew of new investors jumping on board, including Foresite Capital, Janus Henderson Investors, Novo Holdings A/S, and more.
Ray Camahort, Ph.D., Partner at Novo Holdings US, has also joined Obsidian's Board of Directors, signaling a new chapter of growth and innovation for the company. The funds will be channeled towards advancing the clinical development of OBX-115, a groundbreaking engineered cell therapy currently in trials for patients with metastatic melanoma and non-small cell lung cancer.
Obsidian Therapeutics, under the leadership of CEO Madan Jagasia, is at the forefront of pioneering engineered cell and gene therapies. Their proprietary cytoDRiVE® technology is revolutionizing the field by precisely regulating protein function using FDA-approved small-molecule drugs.
The company's lead program, OBX-115, is a novel engineered tumor-derived autologous T cell immunotherapy armed with pharmacologically regulatable membrane-bound IL15 (mbIL15). This innovative therapy holds immense promise for patients with advanced melanoma and other solid tumors, offering enhanced persistence, antitumor activity, and clinical safety.
Obsidian's relentless pursuit of excellence and commitment to patient outcomes make them a force to be reckoned with in the biotech landscape. With this latest funding boost, the company is poised to make significant strides in the development and deployment of cutting-edge therapies that have the potential to transform the lives of patients battling challenging diseases.
Obsidian Therapeutics' unwavering dedication to innovation and patient-centric care sets them apart as a key player in the biotech industry, poised to make a lasting impact on the future of healthcare.
Ray Camahort, Ph.D., Partner at Novo Holdings US, has also joined Obsidian's Board of Directors, signaling a new chapter of growth and innovation for the company. The funds will be channeled towards advancing the clinical development of OBX-115, a groundbreaking engineered cell therapy currently in trials for patients with metastatic melanoma and non-small cell lung cancer.
Obsidian Therapeutics, under the leadership of CEO Madan Jagasia, is at the forefront of pioneering engineered cell and gene therapies. Their proprietary cytoDRiVE® technology is revolutionizing the field by precisely regulating protein function using FDA-approved small-molecule drugs.
The company's lead program, OBX-115, is a novel engineered tumor-derived autologous T cell immunotherapy armed with pharmacologically regulatable membrane-bound IL15 (mbIL15). This innovative therapy holds immense promise for patients with advanced melanoma and other solid tumors, offering enhanced persistence, antitumor activity, and clinical safety.
Obsidian's relentless pursuit of excellence and commitment to patient outcomes make them a force to be reckoned with in the biotech landscape. With this latest funding boost, the company is poised to make significant strides in the development and deployment of cutting-edge therapies that have the potential to transform the lives of patients battling challenging diseases.
Obsidian Therapeutics' unwavering dedication to innovation and patient-centric care sets them apart as a key player in the biotech industry, poised to make a lasting impact on the future of healthcare.